Physician profile
Robert B Allison
NPI 1750339719
$4,931.70
in general payments reported to CMS, 2019-2025
35 companies · $900 in 2025
The $900 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,356 · 2020: $269 · 2021: $773 · 2022: $602 · 2023: $425 · 2024: $607 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,931.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,008.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $574.72 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $366.85 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Amarin Pharma, INC. | $362.83 | 2019-2022 | |
| Astellas Pharma US INC | $362.73 | 2019-2025 | Veozah |
| Amgen INC. | $321.35 | 2019-2025 | Evenity, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $287.46 | 2019-2025 | Gardasil 9, Capvaxive |
| Pfizer INC. | $208.99 | 2019-2025 | |
| Abbvie INC. | $195.18 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $126.16 | 2019-2024 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.43 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $94.57 | 2023-2024 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.61 | 2019-2022 | |
| Sanofi Pasteur INC. | $81.03 | 2024-2025 | |
| Lilly USA, LLC | $76.56 | 2022-2025 | Kisunla, Amyvid |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $69.17 | 2024-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $56.55 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.69 | 2022 | |
| Exact Sciences Corporation | $48.44 | 2024 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $46.42 | 2019-2024 | Eliquis |
| Boston Scientific Corporation | $43.11 | 2025 | Apollo Esg System |
| Dynavax Technologies Corporation | $42.78 | 2022-2025 | Heplisav-B |
| Vertex Pharmaceuticals Incorporated | $41.17 | 2024-2025 | |
| Allergan, INC. | $37.66 | 2020 | |
| Dexcom, INC. | $34.96 | 2025 | Dexcom G6 Transmitter |
| Averitas Pharma INC. | $32.89 | 2025 | Qutenza |
| Bridgebio Pharma, INC. | $28.40 | 2025 | Attruby |
| Gilead Sciences, INC. | $22.54 | 2025 | |
| Adlon Therapeutics L.P. | $22.09 | 2019 | |
| Biogen, INC. | $18.26 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.81 | 2021 | |
| Medtronic Vascular, INC. | $15.61 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.49 | 2022 | |
| Genentech USA, INC. | $14.44 | 2021 | |
| Ironwood Pharmaceuticals, INC | $12.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Allison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.